{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:50:21Z","timestamp":1793915421443,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1067516"],"award-info":[{"award-number":["GNT1067516"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1067516"],"award-info":[{"award-number":["GNT1067516"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victorian Cancer Agency & Snowdome Foundation, Australia","award":["SNOW04"],"award-info":[{"award-number":["SNOW04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>N<\/jats:italic>\n                      -methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and anti-myeloma properties that are partly explained by acetyllysine mimetic properties and non-specific bromodomain inhibition. We therefore evaluated orally administered NMP in a phase 1 dose-escalation trial to establish its maximum tolerated dose (MTD) in patients with relapsed\/refractory multiple myeloma (RR\u2013MM). Secondary endpoints were safety, pharmacokinetics (PK), overall response rate and immunological biomarkers of activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients received NMP at starting doses between 50 and 400\u00a0mg daily. Intra-patient dose escalation occurred in five patients, with one attaining the ceiling protocolised dose of 1\u00a0g daily. Median number of monthly cycles commenced was three (range 1\u201320). Grade 3\u20134 adverse events (AEs) were reported in seven (54%; 95% CI 25\u201381%) patients. Most common AEs (&gt;\u200930% of patients) of any grade were nausea and musculoskeletal pain. The only dose limiting toxicity (DLT) was diarrhoea in a patient receiving 200\u00a0mg NMP (overall DLT rate 8%; 95% CI 0\u201336%). Hence, the MTD was not defined. Median progression-free and overall survival were 57 (range 29\u2013539) days and 33 (95% CI 9.7\u2013\u2009&gt;\u200944) months, respectively. The best response of stable disease (SD) was achieved in nine patients (69%; 95% CI 39\u201391%). PK analysis demonstrated proportional dose\u2013concentrations up to 400\u00a0mg daily, with a more linear relationship above 500\u00a0mg. Maximum plasma concentrations (Cmax) of 16.7\u00a0mg\/L at the 800\u00a0mg dose were below those predicted to inhibit BET-bromodomains. Peripheral blood immune-profiling demonstrated maintenance of natural killer (NK) cells, and a gene expression signature suggestive of enhanced T, B and NK cell functions; a subject with prolonged exposure manifested sustained recovery of B and NK cells at 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NMP demonstrated potential disease stabilising and immunomodulatory activity at sub-BET inhibitory plasma concentrations and was well tolerated in RR\u2013MM; an MTD was not determined up to a maximum dose of 1\u00a0g daily. Further dose-finding studies are required to optimise NMP dosing strategies for therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-023-01427-7","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T09:03:06Z","timestamp":1674896586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma"],"prefix":"10.1186","volume":"15","author":[{"family":"Jake Shortt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Ludford-Menting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Koldej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"1427_CR1","volume-title":"Concise international chemical assessment document 35, International Programme on Chemical Safety","author":"B Akesson","year":"2001","unstructured":"Akesson B. N-methyl-2-pyrrolidone. In: Organisation WH, editor. Concise international chemical assessment document 35, International Programme on Chemical Safety. Geneva: World Health Organisation; 2001."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5271\/sjweh.799","volume":"30","author":"B Akesson","year":"2004","unstructured":"Akesson B, Carnerup MA, Jonsson BA. Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone. Scand J Work Environ Health. 2004;30:306\u201312.","journal-title":"Scand J Work Environ Health"},{"key":"1427_CR3","first-page":"267","volume":"25","author":"B Akesson","year":"1997","unstructured":"Akesson B, Jonsson BA. Major metabolic pathway for N-methyl-2-pyrrolidone in humans. Drug Metab Dispos. 1997;25:267\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00011-015-0833-x","volume":"64","author":"C Ghayor","year":"2015","unstructured":"Ghayor C, Gjoksi B, Siegenthaler B, Weber FE. N-methyl pyrrolidone (NMP) inhibits lipopolysaccharide-induced inflammation by suppressing NF-kB signaling. Inflamm Res. 2015;64:527\u201336.","journal-title":"Inflamm Res"},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.celrep.2014.04.008","volume":"7","author":"J Shortt","year":"2014","unstructured":"Shortt J, et al. The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. Cell Rep. 2014;7:1009\u201319.","journal-title":"Cell Rep"},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1080\/09168451.2014.912114","volume":"78","author":"T Tatsuno","year":"2014","unstructured":"Tatsuno T, Miyazaki K, Yamashiro H. Multiple solvent, N-methyl-2-pyrrolidone, acts as a novel adjuvant for enhancing cutaneous immune responses. Biosci Biotechnol Biochem. 2014;78:954\u20139.","journal-title":"Biosci Biotechnol Biochem"},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"e39817","DOI":"10.1371\/journal.pone.0039817","volume":"7","author":"U B\u00f6nisch","year":"2012","unstructured":"B\u00f6nisch U, et al. Volatile organic compounds enhance allergic airway inflammation in an experimental mouse model. PLoS ONE. 2012;7:e39817.","journal-title":"PLoS ONE"},{"key":"1427_CR8","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1089\/ten.tea.2009.0009","volume":"15","author":"BS Miguel","year":"2009","unstructured":"Miguel BS, et al. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng Part A. 2009;15:2955\u201363.","journal-title":"Tissue Eng Part A"},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bone.2015.05.004","volume":"78","author":"B Gjoksi","year":"2015","unstructured":"Gjoksi B, et al. The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis. Bone. 2015;78:114\u201321.","journal-title":"Bone"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"24458","DOI":"10.1074\/jbc.M111.223297","volume":"286","author":"C Ghayor","year":"2011","unstructured":"Ghayor C, et al. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J Biol Chem. 2011;286:24458\u201366.","journal-title":"J Biol Chem"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"11636","DOI":"10.1038\/s41598-020-68350-2","volume":"10","author":"M Roche-Molina","year":"2020","unstructured":"Roche-Molina M, et al. The pharmaceutical solvent N-methyl-2-pyrollidone (NMP) attenuates inflammation through Kr\u00fcppel-like factor 2 activation to reduce atherogenesis. Sci Rep. 2020;10:11636.","journal-title":"Sci Rep"},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1021\/jm200640v","volume":"54","author":"DS Hewings","year":"2011","unstructured":"Hewings DS, et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011;54:6761\u201370.","journal-title":"J Med Chem"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/jm201320w","volume":"55","author":"CW Chung","year":"2012","unstructured":"Chung CW, Dean AW, Woolven JM, Bamborough P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem. 2012;55:576\u201386.","journal-title":"J Med Chem"},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","volume":"149","author":"P Filippakopoulos","year":"2012","unstructured":"Filippakopoulos P, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214\u201331.","journal-title":"Cell"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"112120","DOI":"10.1016\/j.ejmech.2020.112120","volume":"191","author":"JP Hilton-Proctor","year":"2020","unstructured":"Hilton-Proctor JP, et al. Substituted 1-methyl-4-phenylpyrrolidin-2-ones\u2014fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors. Eur J Med Chem. 2020;191:112120.","journal-title":"Eur J Med Chem"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"115157","DOI":"10.1016\/j.bmc.2019.115157","volume":"27","author":"JP Hilton-Proctor","year":"2019","unstructured":"Hilton-Proctor JP, et al. Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. Bioorg Med Chem. 2019;27:115157.","journal-title":"Bioorg Med Chem"},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1427_CR18","volume-title":"Occupational study in paint stripping industries. Draft report","author":"B Akesson","year":"2000","unstructured":"Akesson B, Jonsson B. Occupational study in paint stripping industries. Draft report. Lund: Lund University; 2000."},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5271\/sjweh.534","volume":"26","author":"B Akesson","year":"2000","unstructured":"Akesson B, Jonsson BA. Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. Scand J Work Environ Health. 2000;26:213\u20138.","journal-title":"Scand J Work Environ Health"},{"key":"1427_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1081\/CLT-100108494","volume":"39","author":"IW Wu","year":"2001","unstructured":"Wu IW, Lin JL, Cheng ET. Acute poisoning with the neonicotinoid insecticide imidacloprid in N-methyl pyrrolidone. J Toxicol Clin Toxicol. 2001;39:617\u201321.","journal-title":"J Toxicol Clin Toxicol"},{"key":"1427_CR21","unstructured":"Sanofi-Aventis, U.S.L. ELIGARD (leuprolide acetate for injectable suspension). Full prescribing information. 2010."},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/jpm11111185","volume":"11","author":"M Costacurta","year":"2021","unstructured":"Costacurta M, He J, Thompson PE, Shortt J. Molecular mechanisms of cereblon-interacting small molecules in multiple myeloma therapy. J Pers Med. 2021;11:1185.","journal-title":"J Pers Med"},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534\u20139.","journal-title":"Blood"},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013346.","journal-title":"Lancet Oncol"},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/bjh.13298","volume":"169","author":"P Asvadi","year":"2015","unstructured":"Asvadi P, et al. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015;169:333\u201343.","journal-title":"Br J Haematol"},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00043764-199607000-00014","volume":"38","author":"GM Solomon","year":"1996","unstructured":"Solomon GM, Morse EP, Garbo MJ, Milton DK. Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. A case report and review of the literature. J Occup Environ Med. 1996;38:705\u201313.","journal-title":"J Occup Environ Med"},{"key":"1427_CR28","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019\u201332.","journal-title":"Blood"},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","volume":"4","author":"JE Davis","year":"2020","unstructured":"Davis JE, et al. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv. 2020;4:4849\u201359.","journal-title":"Blood Adv"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01427-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T09:03:17Z","timestamp":1674896597000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01427-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01427-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2102432\/v1","asserted-by":"object"}]},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"25 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Melbourne Health Human Research Ethics Committee (Ref: 2014.127) and conducted according to the provisions of the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice. All subjects provided informed consent before enrolment. This trial was registered at clinicaltrials.gov; NCT02468687.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS and DR are inventors on patent WO2011160170A1 \u2018stimulating immune response\u2019. There are no other competing interests related to the published work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}